| Literature DB >> 35539527 |
Marc Birringer1, Karsten Siems2, Alexander Maxones1, Jan Frank3, Stefan Lorkowski4,5.
Abstract
We present the first comprehensive and systematic review on the structurally diverse toco-chromanols and -chromenols found in photosynthetic organisms, including marine organisms, and as metabolic intermediates in animals. The focus of this work is on the structural diversity of chromanols and chromenols that result from various side chain modifications. We describe more than 230 structures that derive from a 6-hydroxy-chromanol- and 6-hydroxy-chromenol core, respectively, and comprise di-, sesqui-, mono- and hemiterpenes. We assort the compounds into a structure-activity relationship with special emphasis on anti-inflammatory and anti-carcinogenic activities of the congeners. This review covers the literature published from 1970 to 2017. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35539527 PMCID: PMC9078042 DOI: 10.1039/c7ra11819h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Core structures 2-methyl-3,4-dihydro-2H-chromen-6-ol (1) and 2-methyl-2H-chromen-6-ol (2) with substitution patterns of the chromanol and chromenol ring systems.
Fig. 3Structures and substitution patterns of tocopherols (3 to 9), dehydrotocopherols (10 to 13) and tocotrienols (14 to 19).
Fig. 2Biosynthetic pathway towards the formation of chromanols within photosynthetic organisms. Abr.: HPP: p-hydroxyphenylpyruvate; HGA: homogentisic acid; HPPD hydroxyphenylpyruvate dioxygenase; DOXP: 1-deoxy-d-xylulose-5-phosphate; GG-reductase: geranylgeraniol reductase; DHGG-DP: dihydro-geranylgeraniol diphosphate; THGG-DP: tetrahydro-geranylgeraniol diphosphate; MGGBQ: methyl-geranygeraniol benzoquinol; MTHGGBQ: methyl-tetrahydro-geranylgeraniol benzoquinol; MPBQ: methyl-phytyl benzoquinol; MSBQ: methyl-solanesyl benzoquinol.
Miscellaneous biological activities of chromanols and chromenolsa
| Compound | Activity | Species | Effective concentration | reference |
|---|---|---|---|---|
|
| ||||
| γ-Dehydrotocopherol (12) | Proliferation, wound healing |
| ||
| Desmethyltocotrienol (18) (P21-tocotrienol) | Hypocholesterolemic activity | Chicken | Reduction of total cholesterol (mmol L−1) |
|
| Didesmethyltocotrienol (19) (P25-tocotrienol) | Reduction of LDL cholesterol (mmol L−1) | |||
| δ-Garcinoic acid (30) | Anti-bacterial |
| 1 mm zone of inhibition |
|
| Sargaol (95) | Gastroprotective against HCl/ethanol-induced gastric lessions | Mice | 30 mg kg−1 |
|
| Taondiol (76) | ||||
| Sargachromanol D, F, H, L (57, 59, 61, 65) | Ion pump inhibitor Na+,K+-ATPase |
| IC50: 3.6 μM, 6.0 μM, 4.6 μM, 7.0 μM |
|
| Epitaondiol (79) | Anti-viral | HSV-1 | EC50: 1.34 M |
|
| Strongylophorine 3 (118) | Insecticidal activity |
| EC50: 60 ppm |
|
| Bifurcarenone chromane (94) | Photoprotection | Human fibroblasts | IC50: 5–20 μg ml−1 |
|
| Bifurcarenone chromene (107) | Anti-macroalgal |
| IC50: 2.5 μg ml−1 |
|
| Sargadiol-I (96) | Anthelmintic |
| EC50: 307 μg ml−1 |
|
| 11′,12′-dihydroxy-3,4-dehydro-δ-tocotrienol (102) | Anti-viral | Human cytomegalovirus | IC50 virus absorption: 0.2 μM |
|
| IC50 antiviral activity: 0.49 μM |
| |||
| HSV-1 | 2.8 μM | |||
| HSV-2 | 2.6 μM | |||
| Mumps virus | 7.6 μM | |||
| Measles virus | 2.7 μM | |||
| Adeno virus | 14 μM | |||
| Influenza virus | 4.4 μM | |||
| Poliovirus | 9.0 μM | |||
| Coxsackievirus | 6.8 μM | |||
| 11′,12′-dihydroxy-3,4-dehydro-δ-tocotrienol (102) | Inhibition of bone resorption | Osteoclast-like cells (OCLs) | IC50: ∼8 μM |
|
| Sarcochromenol sulfate A (110) | Ion pump inhibitor Na+,K+-ATPase | IC50: 1.6 μM |
| |
|
| ||||
| Chromazonarol (154) | Algicidal activity |
| Mean mortality after 4h at 1 μg ml−1: |
|
|
| 78% | |||
|
| 42% | |||
| 93% | ||||
|
| ||||
| Cordiachromene A (173) | Anti-bacterial |
| 2–64 μg ml−1 |
|
|
| 1–64 μg ml−1 | |||
|
| MIC > 2 mmol |
| ||
|
| MIC > 0.51 mmol | |||
| Didehydroconicol (185) | Anti-bacterial |
| MIC > 2 mmol, MIC > 0.51 mmol |
|
| Epiconicol (184) | MIC > 2 mmol, MIC > 0.13 mmol | |||
| Cymobarbatol (181) and 4-isocymobarbatol (182) | Antimutagenic inhibition of 2AN and EMS mutagenicity towards | T-98 stain | 75, 150 and 300 μg/plate |
|
| T-100 stain | (EMS): 32.5–300 μg/plate | |||
|
| ||||
| Precocene 2 (194) | Anti juvenile hormone | Induction of precocious metamorphosis in milkweed bug | 0.7 μg cm−2 90% precocious adults |
|
| Daedalin A (199) | Inhibition of melanin synthesis | Tyrosinase inhibition | IC50: 194 μM |
|
Abbreviations: herpes simplex virus 1 and 2 (HSV-1 and -2), minimum concentration that inhibits (MIC) bacterial growth, 2-aminoanthracene (2AN), ethyl methanesulfonate (EMS).
Estimated from original publication.
Fig. 4Structures and substitution patterns of formyl derivatives (20) and (21), tocomonoenols (22 to 24), tocodienol (26) and plastochromanols (27 to 29).
Fig. 5Structures and substitution patterns of garcinoic acids (30 to 33) and meroditerpenes (34 to -40) from Garcinia amplexicaulis.
Fig. 6Structures and substitution patterns of litchtocotrienols (41 to 48) from Litchi chinensis, sargachromenols (51) and (52).
Fig. 7Scheme of an acid-catalyzed cyclization cascade including final cyclization of the chromane ring according to Etse et al.[61] Examples are cyclolitchtocotrienol (49) and walsurol (50).
Cytotoxic activities of by chromanols and chromenols against cancer cellsa
| Compound | Isolated from | Cell line/organism | Effective concentration | Reference |
|---|---|---|---|---|
|
| ||||
| α-Tocopherol (3) | Plant oils | HepG2 cells, | >100 μM |
|
| MDA-MB-231, MCF7 cells | Not achieved |
| ||
| γ-Tocopherol (5) | Plant oils | Jurkat, HBTII, MCF7, MCF7-C3 cells | >50 μM |
|
| δ-Tocopherol (6) | Plant oils | Jurkat, HBTII, MCF7, MCF7-C3 cells | >50 μM |
|
| α-Tocotrienol (14) | Palm oil | MDA-MB-435, MCF7, B16 cells | IC50: 210 μM, 14 μM, 110 μM |
|
| MDA-MB-231, MCF7 cells | IC50: 24 μM, 26 μM |
| ||
| γ-Tocotrienol (16) | Jurkat, HBTII, MCF7, MCF7-C3 cells | ∼50%, 35%, 30%, 35% at 50 μM |
| |
| MDA-MB-231, MCF7 cells | IC50: 11 μM, 15.6 μM |
| ||
| SKBR3 cells, BT474 cells | IC50: 4.1 μM, 4.4 μM |
| ||
| δ-Tocotrienol (17) | MCF7, B16 cells | IC50: 15 μM, 10 μM |
| |
| MDA-MB-231, MCF7 cells | IC50: 17 μM, 17 μM |
| ||
| Sargaol (95) |
| Human epithelial gastric cells | IC50: 18 μM |
|
| Human fibroblasts | IC50: 12 μM | |||
|
| P338 leukemia cells | EC50: 52 μM |
| |
| Desmethyltocotrienol (18) (P21-tocotrienol) | Rice bran | B16 cells (suppression of proliferation) | IC50 > 1 μM |
|
| Didesmethyltocotrienol (19) (P25-tocotrienol) | IC50: 0.9 μM |
| ||
| 13′-Carboxy-δ-tocopherol (229) | Semisynthetic from | Glioma C6 cells | n.d. |
|
| HepG2 cells | EC50: 6.5 μM (δ-13-COOH) |
| ||
| THP-1 macrophages | EC50: 11.1 μM (δ-13-COOH) |
| ||
| HCT-116 cells | EC50: 8.9 μM (δ-13-COOH) |
| ||
| HT-29 | EC50: 8.9 μM (δ-13-COOH) | |||
| 13′-Hydroxy-α-tocopherol (204) | HepG2 cells | EC50 > 100 μM |
| |
| THP-1 macrophages | EC50 > 100 μM |
| ||
| 13′-Carboxy-α-tocopherol (205) | HepG2 cells | EC50: 13.5 μM (α-13-COOH) |
| |
| THP-1 macrophages | EC50: 7.4 μM (α-13-COOH) |
| ||
| δ-Garcinoic acid (30) |
| Glioma C6 cells | EC50: 10 μM |
|
| RAW264.7 macrophages | EC50: 5.5 μM |
| ||
| HCT-116 cells | EC50: 16 μM (δ-garcinoic acid) |
| ||
| HT-29 | EC50: 17 μM (δ-garcinoic acid) | |||
| Inhibition of DNA polymerase β | IC50: 4 μM |
| ||
| δ-Sargachromenol (51) |
| Caspase-3 induced apoptosis in HaCaT cells | EC60: 11.8 μM |
|
| Fallachromenoic acid (105) |
| P338 leukemia cells | IC50 > 27–29 μM |
|
| δ-Amplexichromanol (35) |
| Antiangiogenicity in VEGF-induced HUVECs | Effective at 25 nM and 2.5 μM |
|
| γ-Amplexichromanol (36) | ||||
| Litchtocotrienol A-G (41–47) |
| HepG2 cells | IC50: 11.1 (A), 14.2 (B), 22.7 (C), 10.7 (E), 12.3 (F), 34.1 (G) μM |
|
| AGS cells | IC50: 10.9 (A), 32 (B), 24.2 (C), 26.8 (D), 27.4 (E), 49.2 (F) 43.2 (G) μM | |||
| Crassumtocopherol A (134) |
| P338 leukemia cells | IC50: 6.7 μM |
|
| IC50: 5.2 μM | ||||
| Crassumtocopherol B (135) | Cytotoxicity in HT-29 cells | IC50: 7.5 μM | ||
| Sargachromanol E (58) |
| Caspase-3 induced apoptosis in promyelocytic HL-60 leukemia cells | EC50: 20 μM |
|
| Sargatriol (98) |
| P-338 leukemia cells | EC50: 42 μM |
|
| Sargadiol-I (96) | EC50: 34 μM |
| ||
| Sargadiol-II (97) | EC50: 41 μM | |||
| Sargadiol I (96) |
|
| EC50: 233 μM |
|
| Epitaondiol (79) |
| Human epithelial gastric cells | IC50: 29 μM |
|
| Human fibroblasts | IC50: 19 μM | |||
| RAW 264.7 | IC50: 12.7 μM |
| ||
| Isoepitaondiol (78) | Human epithelial gastric cells | IC50: 42 μM |
| |
| Human fibroblasts | IC50: 65 μM | |||
| Neuro-2a cell line | LC50: 2 μM |
| ||
| NCI-H460 | LC50: 24 μM | |||
| Macrolitchtocotrienol A (48) |
| HepG2 cells | IC50: 16.5 μM |
|
| Cystoseirol A (86) |
| Crown-gall potato bioassay | 73% tumor inhibition at 10−2 M |
|
| Demethoxy cystoketal chromane (89) |
| Cytotoxicity in HepG2 cells | IC50: 35 μM |
|
|
| ||||
| Strongylophorine 2 (117) |
| Cytotoxicity in HeLa cells | IC50: >100 μM |
|
| Strongylophorine 3 (118) | IC50: 45.2 μM | |||
| Strongylophorine 4 (119) | IC50: 50.5 μM | |||
| Strongylophorine 22 (128) | IC50: 26.6 μM | |||
| Strongylophorine 23 (129) | IC50: 62.0 μM | |||
| Strongylophorine 24 (130) | IC50: >100 μM | |||
|
| ||||
|
| ||||
| Riccardiphenol C (146) |
| P338 leukemia cells | IC50 > 80 μM |
|
| Aureol (155) |
| A549, | IC50: 13.6 μM |
|
| HT-29, | IC50: 14.9 μM | |||
| EL-4 | IC50: 31.5 μM | |||
| Panicein A2 (160) |
| P388, A549, MEL20, HT29 | EC50: 14.8 μM |
|
| Panicein F2 (161) | EC50: 14.2 μM | |||
|
| ||||
| Cordiachromene A (173) |
| Human carcinoma KB | CI50: 14.3 μM |
|
| Murine leukemic P388 | CI50: 20.5 μM | |||
|
| Lymphoblastic leukemia CEM-WT cells | IC50: 30 μM |
| |
| Didehydroconicol (185) |
| Lymphoblastic leukemia CEM-WT cells | IC50: > 10 mM |
|
| Epiconicol (184) | IC50: 60 mM | |||
| Didehydroconicol (185) |
| Sea urchin eggs of | IC50: >25 μM and 9.8 μM |
|
| Epiconicol (184) | IC50: >11.3 μM and >25 μM | |||
| Chaetopyranin (188) |
| HMEC, SMMC-7721, A549 | IC50: 49 μM, 90 μM, 124 μM |
|
| α-CEHC (208) | Human metabolites | Growth inhibition at 50 μM |
| |
| γ-CEHC (233) | Prostate cancer PC-3 | 42% (α-), 83% (γ-) | ||
| HTB-82 | 34% (α-), 58% (γ-) | |||
| HECV | 9% (α-), 19% (γ-) | |||
| Sargasal-I (176) |
| P-338 leukemia cells | EC50: 20.3 μM |
|
| Sargasal-II (177) | EC50: 21 μM |
| ||
|
| ||||
| Mollugin (189) |
| MCF-7/adriamycin | IC50 of doxorubicin decreased from 60 to 7.5 μg ml−1 at 10 μM mollugin |
|
Abbreviation: human gastric adenocarcinoma cells (AGS), human microvascular endothelial cells (HMEC), hepatocellular carcinoma cells (SMMC-7721), human lung epithelial cells (A549), human hepatocellular carcinoma cells (HepG2), B16 melanoma cells, vascular endothelial growth factor (VEGF), human umbilical vein endothelial cells (HUVEC).
Estimated from original publication.
For better comparison μg ml−1 were converted to μM.
Fig. 8Structures and substitution patterns of sargachromanols (56 to 68) from Sargassum species.
Fig. 9Structures and substitution patterns of sargachromanols (69 to 75) from Sargassum species.
Fig. 10Proposed enzyme-catalyzed cyclization leading to cyclic sargachromanols (76 to 80).
Fig. 11Structures of mediterraneols (82 to 84), cystophloroketal E (85), cystoseirols (86 to 88), chromanes (90 to 92), (94) and cystoseirone (93) from Cystoseira species. Bifurcarenone (81) as the common biosynthetic precursor is depicted in the center of the figure.
Fig. 12Structures of sargachromenols (95 to 101) from Sargassum species.
Inhibition of inflammatory markers by chromanols and chromenolsa
| Compounds | Test system | Effective concentrations | References |
|---|---|---|---|
|
| |||
| α-Tocopherol (3) | IL-1β-stimulated A549 cells | 8% nitric oxide inhibition at 10 μM |
|
| 25% iNOS inhibition at 10 μM | |||
| IC50 PGE2 inhibition: > 50 μM (A549 cells) | |||
| γ-Tocopherol (5) | IL-1β-stimulated A549 cells | IC50 PGE2 inhibition: 7.5 μM (RAW264.7) |
|
| IC50 5-LOX inhibition: > 50 μM |
| ||
| IC50 COX-2 (A549 cells) inhibition: > 50 μM | |||
| δ-Tocopherol (6) | IL-1β-stimulated A549 cells | IC50 COX-2 (A549 cells)) inhibition: > 50 μM |
|
| IC50 5-LOX inhibition: > 50 μM | |||
| IC50 PGE2 inhibition: 3 μM (A549 cells) | |||
| α-Tocotrienol (14) | LPS-induced RAW 264.7 cells | 5% NO inhibition at 33 μM |
|
| δ-Tocotrienol (17) | 31% NO inhibition at 26 μM | ||
| γ-Tocotrienol (16) | 19% NO inhibition at 30 μM | ||
| IL-1β-stimulated A549 cells | IC50 PGE2 inhibition: 1 μM (A549 cells) |
| |
| 13′-carboxy-α-tocopherol (205) (α-13′-COOH) | LPS-induced RAW 264.7 cells | Total inhibition at 2.7 μM |
|
| IC50 NO production: 0.2–0.5 μM | |||
| LPS-induced RAW 264.7 cells | 88% NO inhibition at 5 μM |
| |
| 100% iNOS inhibition at 5 μM | |||
| 13′-carboxy-δ-tocopherol (229) (δ-13′-COOH) | Inhibition of COX-1 and COX-2 | IC50 COX-1 (bovine) inhibition: 5.0 μM |
|
| IC50 COX-2 (human) inhibition: 4.0 μM |
| ||
| IC50 COX-2 (A549 cells)) inhibition: 4.0 μM |
| ||
| Inhibition of human recombinant 5-LOX | IC50 5-LOX inhibition: 0.5–1.0 μM |
| |
| IC50 (LTB4) generation: 4–7 μM | |||
| Neutrophils and promyelocytic HL-60 | |||
| Leukemia cells generated LTB4 | 79% NO inhibition at 5 μM | ||
| LPS-induced RAW 264.7 cells | 56% iNOS inhibition at 5 μM |
| |
| 13′-Hydroxy-α-tocopherol (204) (α-13′-OH) | LPS-induced RAW 264.7 cells | 49% COX-2 inhibition at 10 μM |
|
| 53–60% iNOS inhibition at 10 μM | |||
| 54% PGE2 inhibition at 10 μM | |||
| 44–69% NO inhibition at 10 μM | |||
| 13′-Hydroxy-δ-tocopherol (231) (δ-13′-OH) | LPS-induced RAW 264.7 cells | 49% NO inhibition at 10 μM |
|
| 53% iNOS inhibition at 10 μM | |||
| δ-Garcinoic acid (30) | Inhibition of COX-2 and 5-LOX | IC50 COX-2 inhibition: 9.8 μM |
|
| IC50 5-LOX inhibition: 1.0 μM | |||
| Inhibition of LPS-stimulated NO production in RAW 264.7 macrophages | IC50 NO production: 1.0 μM |
| |
| α-, β-,< γ-,< δ-Garcinoic acid (209, 232, 231, 230) | Inhibition of PGE2-synthase (PGES-1) | IC50 7.8 (α-), 2.8 (β-), 2.0 (γ-), 6.7 (δ-) garcinoic acid |
|
| δ-Sargachromenol (51) | TPA-induced mouse ear edema | IC50 edema reduction: 0.36 mg per ear |
|
| Inhibition of COX-1 and -2 | 98% COX-1 inhibition at 100 ppm |
| |
| 84% COX-2 inhibition at 100 ppm | |||
| LPS-induced RAW 264.7 and BV-2 cells | IC50 NO production: 82 μM (RAW264.7) |
| |
| IC50 PGE2 inhibition: 30.2 μM (RAW264.7) | |||
| IC50 NO production: 1.3–2.7 μM (BV-2) |
| ||
| Sargachromanol D (57) | LPS-induced RAW 264.7 cells | IC50 NO production: 40 μM |
|
| IC50 PGE2 inhibition: 15 μM | |||
| Sargachromanol E (58) | LPS-induced RAW 264.7 cells | IC50 NO production: 16.3 μM |
|
| Sargachromanol G (60) | LPS-induced RAW264.7 cells | IC50 NO production: Ca. 15 μM |
|
| Chromarols (A–D) (113–116) | Inhibitors of 12- and 15-LOX | 15-hLO IC50: 0.6(A), 4.0(B), 0.7(C), 1.1 μM(D) |
|
| 12-hLO IC50: all >100 μM | |||
| Epitaondiol (79) | TPA-induced mouse ear edema | IC50 edema reduction: 20.7 μg per ear |
|
| IC50 myeloperoxidase activity: 17.8 μg per ear | |||
| Eicosanoid inhibition | IC50 (TXB2) generation: 3.8 μM |
| |
| IC50 (LTB4) generation: 30.1 μM | |||
|
| |||
| Capillobenzopyranol (172) | LPS-induced RAW 264.7 cells | 36.7% NO inhibition at 10 μM |
|
| 9′-Carboxy-δ-tocopherol (206) (δ-9′-COOH) | Inhibition of COX-1, -2 | IC50 COX-1 (bovine) inhibition: >20 μM |
|
| IC50 COX-2 (human) inhibition: >20 μM | |||
| IC50 COX-2 (A549 cells)) inhibition: 6.0 μM | |||
|
| |||
| Cordiachromene A (173) | Inhibition of PGI2 biosynthesis | IC50 8.2 μM |
|
| Carrageenan induced rat paw endema | IC50 18.9 μM |
| |
| Inhibitor of 15-LOX | IC50: 0.82 μM |
| |
| IC50: 2 μM | |||
| α-CMBHC (207) | IC50 COX-1 (bovine) inhibition: 160 μM |
| |
| IC50 COX-2 (human) inhibition: 140 μM | |||
| α-CEHC (208) | TNFα-stimulated NO and PGE2 production in RAEC cells | IC50 PGE2 inhibition: 59 μM |
|
| IC50 NO production: 56 μM | |||
| γ-CEHC (233) | IC50 COX-1 (bovine) inhibition: 300 μM |
| |
| IC50 COX-2 (human) inhibition: 450 μM | |||
| IC50 COX-2 (A549 cells)) inhibition: 35–70 μM | |||
| IC50 PGE2 inhibition: 30.0 μM (RAW 264.7) |
| ||
|
| |||
| Quercinol (199) |
| IC50 COX-1 inhibition: 4.7 μM |
|
| IC50 COX-2 inhibition: 0.63 μM | |||
| IC50 3α-HSD inhibition: 114 μM | |||
| IC50 XO inhibition: 21 μM | |||
| IC50 HRP: 68 μM | |||
Abbreviations: thromboxane B2 (TXB2), leukotriene B4 (LTB4), cyclooxygenase (COX)-1 and -2, 3α-hydroxysteroid dehydrogenase (3α-HSD), lipoxygenase (LOX), xanthine oxidase (XO), horseradish peroxidase (HRP).
Estimated from original publication.
Fig. 13Structures of sargachromenols (102 to 107) from Sargassum species.
Fig. 14Structures of meroditerpenoids (25) and (108) from phytoplankton and sarcochromenols (110 to 112) from Sarcotragus spinulosus.
Fig. 15Structures of chromarols (113 to 116) from Psammocinia species.
Fig. 16Structures of strongylophorines (117 to 130) from Strongylophora species.
Fig. 17Structures of tuberatolide (131) from the tunicate Botryllus tuberatus and meroditerpenoids (132 to 135) from soft corals.
Fig. 18Structures of plant sesquiterpenes (136 to 146).
Fig. 19Structures of sesquiterpenes (147 to 152) from fungi species.
Fig. 20Scheme of multiple acid-catalyzed cyclizations of farnesyl hydroquinone towards chromazoranol (154) as suggested by Kurata et al.[186] Structures of cyclic (157) and linear sesquiterpenoids (54, 55, 72 and 153).
Fig. 21Structures of sesquiterpenes (155 to 161) from sponge species.
Fig. 22Structures of ansa chromane macrocycles (162 to 167) from Smenospongia species and (168) from tunicate.
Fig. 23Structures of sesquiterpenes (169–171) from marine nudibranchs and soft coral (172).
Fig. 24Structures of monoterpenes (173 to 185) from plants, marine algae and tunicates.
Fig. 25Structures of monoterpenes (186 to 188) from tunicates and algal derived endophytic fungi.
Fig. 26Structures of hemiterpenes (189 to 198) from plant species.
Fig. 27Structures of hemiterpenes (199 to 202) from plants and fungi.
Fig. 28Mammalian metabolism of tocopherols and tocotrienols. α-TOH: α-tocopherol; α-tocotrienol: α-tocotrienol; 13′-OH: 13′-hydroxy-chromanol; 13′-COOH: 13′-carboxy-chromanol; CDMD(en)2HC: carboxy-dimethyl-decadienyl-hydroxy-chromanol; CDMOenHC: carboxy-dimethyl-octenyl-hydroxy-chromanol; CDMHenHC: carboxy-methyl-hexenyl-hydroxy-chromanol; CMBenHC: carboxy-methyl-butadienyl-hydroxy-chromanol; CDMOHC: carboxy-methyl-octyl-hydroxy-chromanol; CDMHHC: carboxy-methyl-hexyl-hydroxy-chromanol; CMBHC: carboxy-methyl-butyl-hydroxy-chromanol; CEHC: carboxy-ethyl-hydroxy-chromanols.
Fig. 29General domains modulating the anti-inflammatory activity of meroterpenoids.
Fig. 30General structural motives important for the anti-cancer activities of meroterpenoids.
Fig. 31Statistical distribution of meroterpenoids.